The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Detecting intratumoral microorganisms and their impact on outcomes in patients with DLBCL
Paola Ghione, MD, MSEpi, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the discovery of intratumoral microorganisms in diffuse large B-cell lymphoma (DLBCL) and their impact on patient outcomes. Using a bioinformatic pipeline to identify sequences of microorganisms, Dr Ghione and her team found that the Prevotella family was associated with better outcomes, while the Enterococcus family was linked to worse overall survival. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In this work we used a bioinformatic pipeline to look for sequences of microorganisms directly inside the tumor. This is the first time that this is done in lymphoma in general and in diffuse large B-cell lymphoma we found a particularly high presence of microorganisms. We don’t know yet whether that is related to the inflammation of the lymphoma but certainly some of these microbes are related to outcomes for patients who get standard chemoimmunotherapy...
In this work we used a bioinformatic pipeline to look for sequences of microorganisms directly inside the tumor. This is the first time that this is done in lymphoma in general and in diffuse large B-cell lymphoma we found a particularly high presence of microorganisms. We don’t know yet whether that is related to the inflammation of the lymphoma but certainly some of these microbes are related to outcomes for patients who get standard chemoimmunotherapy. And so for example the Prevotella family bacteria was associated to a better outcome in diffuse large B-cell lymphoma and it was present in approximately 40% of the samples, so 40% of the DLBCL, while the presence of Enterococcus was related to a worse overall survival. And both the progression-free survival and the overall survival in the Prevotella and Enterococcus were independent of the other variables related to outcome. I think, you know, it’s really interesting. We don’t know yet how these bacteria got there, whether they came from the gut or from other sites, but it is certainly something we want to work on, especially related to the microenvironment that could be either influenced or influence the presence of these bacteria.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
